Optimized pharmacological treatment for broken heart (takotsubo) syndrome
Phase 1
- Conditions
- The medical condition is acute heart failure (Takotsubo syndrome)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2020-002708-38-SE
- Lead Sponsor
- Department of Medical Science Gothenburg University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
A clinical diagnosis of Takotsubo syndrome
Age above 18 years
Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 700
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 300
Exclusion Criteria
Any contra indication for treatment with adenosine or dipyridamole
Ongoing treatment with dipyridamole
Life expectancy of less than one month
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method